Skip to content
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

ProPhase Labs, Inc. PRPH

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$4.3M
▼ 35.8% YoY
$-14.7M
$-8.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We are a growth oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. We offer whole genome sequencing and related services through our wholly-owned subsidiary, Nebula Genomics, Inc. (“Nebula”) and DNA Complete, Inc. ("DNA Complete"). Our wholly owned subsidiary, ProPhase BioPharma, Inc. (“PBIO”) is focused on the licensing, development and commercialization of novel drugs, dietary supplements, and compounds. We also develop and market dietary supplements under the TK Supplements® brand. We own the exclusive rights to the BE-Smart Esophageal Pre-Cancer diagnostics screening test and related intellectual property assets. Currently, we plan to commercialize the BE-Smart test as a Laboratory Developed Test (“LDT”).

Written from the business description in ProPhase Labs, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 1 June 2026. Every sentence was checked against that document before publication.

Growth

USD 4.3M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 4.3 · Net income -14.7
50M100M-20M-40M
2009201220152018202120242025
Compound annual growth
−67.2%
−21.4%
+5.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −21.4% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−339 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -415.4% · Net -339.3%
200%400%-200%-400%-600%
200920172025
ROE
FY2025 · ROE -271.5%
100%200%-100%-200%
200920172025
Three returns, three denominators.

Each USD of equity lost 271 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -8.3
10M20M-10M-20M
200920172025
Net buybacks $M Dividends $M
FY2024 · Dividends · · Net buybacks 0.0
10M20MDividendsNet buybacks
2017201820192021202220232024

Total assetsUSD 59.9M
EquityUSD 3.5M
CashUSD 90,000.00
Current ratio0.06×

Equity funds 6% of total assets.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
PRPH, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.00.00.00.10.10.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0
Income tax $B0.00.0−0.00.0−0.00.0◌0.0−0.0◌◌0.00.00.00.0−0.0−0.0
Net income $B−0.0−0.1−0.00.00.0−0.0−0.0−0.00.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.00.0
EPS, diluted $−1.74−26.68−0.981.020.40−0.18−0.27−0.152.59−0.17−0.22−0.470.03−0.07−0.18−0.25−0.30
Dividend / sh $◌◌◌◌0.30◌◌◌◌◌◌◌◌◌◌◌◌
Payout %——−05172—−185−672—————————
ROE %−271.5−188.1−29.730.218.1−19.5−22.7−7.2214.7−38.8−36.8−67.23.4−9.6−22.0−25.4−27.3
Shares out B0.010.030.020.020.020.01◌◌◌◌◌◌◌◌◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 82 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: the share count is not tagged before 2010. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image